The following is a summary of the Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Pulse Biosciences reported an increase in its Non-GAAP total costs and expenses, rising by $1.2 million to $8.9 million in Q4 2023 due to heightened R&D expenses.

• The non-GAAP net loss for Q4 2023 was at $8.3 million, slightly up from $8.1 million compared to the same period last year.

• Cash and equivalents decreased to $44.4 million at the end of Q4 2023 from $50.4 million as recorded in Q3 2023.

• The company also launched a rights offering, with potential gross proceeds of up to $60 million and additional proceedings of potentially $66 million upon exercise of all warrants.

Business Progress:

• Pulse Biosciences made significant advancements with their CellFX nsPFA energy delivery system and three novel endofactor devices, with one receiving FDA 510(k) clearance for soft tissue ablation and the two others in varying stages of FDA clearance and study.

• The company is working towards the commercialization of their percutaneous electrode for benign thyroid nodule ablation, and is optimizing their procedure with key opinion leaders.

• They are planning to start a first in-human feasibility study for their cardiac clamp due to high interest from cardiac surgeons.

• Additionally, the company is preparing the required infrastructure to commercialize their clamp product.

• The firm is also exploring compatibility with multiple mapping and navigation systems for their catheter, including systems like Carto and EnSite.

• Future updates on progress are expected to be given on a quarterly basis.

More details: Pulse Biosciences IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.